Sera Prognostics Inc
NASDAQ:SERA
Intrinsic Value
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. [ Read More ]
The intrinsic value of one SERA stock under the Base Case scenario is 4.43 USD. Compared to the current market price of 9.72 USD, Sera Prognostics Inc is Overvalued by 54%.
Valuation Backtest
Sera Prognostics Inc
Run backtest to discover the historical profit from buying and selling SERA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Sera Prognostics Inc
Current Assets | 61.3m |
Cash & Short-Term Investments | 49.1m |
Receivables | 11.5m |
Other Current Assets | 795k |
Non-Current Assets | 34.1m |
Long-Term Investments | 30.8m |
PP&E | 3.2m |
Other Non-Current Assets | 77k |
Current Liabilities | 24.4m |
Accounts Payable | 1m |
Accrued Liabilities | 1.8m |
Other Current Liabilities | 21.6m |
Non-Current Liabilities | 840k |
Long-Term Debt | 196k |
Other Non-Current Liabilities | 644k |
Earnings Waterfall
Sera Prognostics Inc
Revenue
|
306k
USD
|
Cost of Revenue
|
-210k
USD
|
Gross Profit
|
96k
USD
|
Operating Expenses
|
-39.9m
USD
|
Operating Income
|
-39.8m
USD
|
Other Expenses
|
3.6m
USD
|
Net Income
|
-36.2m
USD
|
Free Cash Flow Analysis
Sera Prognostics Inc
What is Free Cash Flow?
SERA Profitability Score
Profitability Due Diligence
Sera Prognostics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Sera Prognostics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
SERA Solvency Score
Solvency Due Diligence
Sera Prognostics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Sera Prognostics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SERA Price Targets Summary
Sera Prognostics Inc
According to Wall Street analysts, the average 1-year price target for SERA is 2.75 USD .
Ownership
SERA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SERA Price
Sera Prognostics Inc
Average Annual Return | -59.24% |
Standard Deviation of Annual Returns | 33.5% |
Max Drawdown | -91% |
Market Capitalization | 310.4m USD |
Shares Outstanding | 32 430 000 |
Percentage of Shares Shorted | 0.8% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 115 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The firm's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.
Contact
IPO
Employees
Officers
The intrinsic value of one SERA stock under the Base Case scenario is 4.43 USD.
Compared to the current market price of 9.72 USD, Sera Prognostics Inc is Overvalued by 54%.